US Chamber of Commerce / Pugatch Consilium — Fourteenth Edition
Stacked bars show each country's score broken down by IP category. Israel is highlighted in gold.
Countries colored by performance tier. Israel highlighted with a gold border.
Select a country to view its overall score, year-over-year change, and full indicator breakdown.
Explore how all 55 economies rank within a specific IP category. Israel's position is highlighted.
Israel is fixed as the baseline. Select up to 3 additional countries to compare across all 10 IP categories.
Direct quotes from the 2026 International IP Index, 14th Edition (pp. 189–193).
Global leader on technology transfer and international licensing activity; no administrative or regulatory barriers in place.
Life sciences IP rights reform efforts have considerably strengthened Israel's IP environment.
Generous R&D and IP specific tax incentives in place.
Israeli Patent Office active participant in all major PPH tracks.
2019 copyright amendments strengthened enforcement against online infringement and introduced possibility of injunctive style relief.
Since the IP policy reforms, biopharmaceutical foreign direct investment into Israel has surged, and, importantly, the reforms have not had a negative impact on the domestic generics industry.
No special IP incentives for orphan medicinal product development.
Current pre-grant patent opposition proceedings create long delays to patent prosecution.
Israel has fought hard to strengthen its national IP environment. The introduction of a manufacturing and export exemption to the existing patent term restoration regime would be a significant setback.
More limited participation in international treaties than other high-income OECD economies.
Unclear if current RDP term applies to large molecule products.
As the Index has repeatedly noted, regardless of the merits of any opposition filing, these generous timelines impose a significant burden and delay on the patent prosecution process in Israel.
Israel's overall score has increased from 36.62 out of 53 indicators in the 13th edition to 36.63. This reflects a score increase on indicator 32 [Physical counterfeiting rates].
In early 2025, the Israeli Patent Office introduced “Memorandum of the Patent Law (Amendment No. 15), 5785-2025” to change the Patent Law. The proposed amendments seek to change existing practices relating to grace periods; the introduction of a new provisional filing system; new limitations on divisional applications; and other important changes.
This is a highly negative development and comes five years after the Israeli Government's 2020 authorization of a compulsory license for the antiviral drug lopinavir/ritonavir. These negative developments undermine the substantive progress made over the last 20 years to strengthen Israel's national IP environment.